checkAd

     862  0 Kommentare REPEAT – AgraFlora’s Subsidiary Farmako Secures Additional Supply of EU-GMP Cannabis via Definitive Supply Agreement with ZenPharm Limited - Seite 2

    About Farmako GmbH
    Farmako GmbH is a pharmaceutical wholesaler based in Frankfurt, Germany. The company focuses on the distribution of medical cannabis to pharmacies with the aim of securing the supply for cannabis patients and closing the gap between supply and demand for medical cannabis. Farmako is planning to expand its business model into other European countries with a corresponding legal basis, scaling towards its goal of being Europe’s leading distributor of medicinal cannabis. The company already distributes medical cannabis to pharmacies in Germany since March 2019 and is fully licenses in the UK to start distribution operations there in 2020. Farmako is a 100% subsidiary of AgraFlora Organics International Inc. For more information please visit: https://www.farmako-global.com/.

    ON BEHALF OF THE BOARD OF DIRECTORS
    Nicholas Konkin
    E: ir@agraflora.com
    T: (800) 783-6056

    For French inquiries:
    Maricom Inc.
    Remy Scalabrini
    E: rs@maricom.ca
    T: (888) 585-MARI

    The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

    Forward-looking Information Cautionary Statement
    Except for statements of historic fact this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan” “expect” “project” “intend” “believe” “anticipate” “estimate” and other similar words or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including but not limited to delays or uncertainties with regulatory approvals including that of the CSE. There are uncertainties inherent in forward-looking information including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators which are available at www.sedar.com.

    Lesen Sie auch

     


    Seite 2 von 2



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    REPEAT – AgraFlora’s Subsidiary Farmako Secures Additional Supply of EU-GMP Cannabis via Definitive Supply Agreement with ZenPharm Limited - Seite 2 VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) - AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that its wholly owned subsidiary Farmako GmbH …